Trial Profile
A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Celecoxib; Diclofenac; Naproxen
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OA SAFETY STUDY
- Sponsors Eli Lilly and Company; Pfizer
- 01 Dec 2023 Results of a pooled analysis assessing Joint safety events from 3 phase 3 clinical studies (NCT02697773, NCT02709486 and NCT02528188) published in the Osteoarthritis and Cartilage
- 01 Nov 2022 A post-hoc analysis of data from two pooled placebo-controlled studies and one NSAID-controlled study of subcutaneous tanezumab( NCT02697773; NCT02709486; NCT02528188) assessing efficacy and safety of subcutaneous tanezumab, nonsteroidal anti-inflammatory drugs (NSAIDs), and placebo in patients with osteoarthritis (OA) and a history of these conditions published in the Current Medical Research and Opinion
- 27 Oct 2022 Data from 3 studies (NCT02528188, NCT02709486 & NCT02697773) assessing analgesic response to daily oral nonsteroidal anti-inflammatory drugs (NSAIDs) or subcutaneous tanezumab at week 16 in patients with moderate-to-severe osteoarthritis, published in the Advances in Therapy.